Skip to content

CytomX Therapeutics, Inc.: filings

Every CytomX Therapeutics, Inc. annual and quarterly report in the SEC record with the published financial measures it tagged, 45 filings, each linked to its SEC index.

Filings with published measures

Each page shows what one filing reported, as tagged in that filing, with the periods it covered. Later filings can restate a value; the company overview shows the latest-filed value per period.

FormFiledFiscal periodMeasuresFactsSEC accession
10-Q2026-08-06fiscal Q2 2026431210001193125-26-337950
10-Q2026-05-07fiscal Q1 202643890001193125-26-211868
10-K2026-03-16fiscal FY 2025501020001193125-26-107146
10-Q2025-11-06fiscal Q3 2025421210001193125-25-269477
10-Q2025-08-07fiscal Q2 2025421170000950170-25-104991
10-Q2025-05-12fiscal Q1 202541840000950170-25-068511
10-K2025-03-06fiscal FY 2024511010000950170-25-034575
10-Q2024-11-07fiscal Q3 2024421200000950170-24-123249
10-Q2024-08-08fiscal Q2 2024421160000950170-24-093865
10-Q2024-05-08fiscal Q1 202441840000950170-24-055588
10-K2024-03-11fiscal FY 2023501000000950170-24-029191
10-Q2023-11-07fiscal Q3 2023411200000950170-23-060201
10-Q2023-08-08fiscal Q2 2023391080000950170-23-039761
10-Q2023-05-09fiscal Q1 202338800000950170-23-019654
10-K2023-03-27fiscal FY 2022481780000950170-23-009991
10-K/A2023-03-27fiscal FY 2021512940000950170-23-009984
10-Q2022-11-08fiscal Q3 2022401140000950170-22-023190
10-Q2022-08-04fiscal Q2 2022401100000950170-22-014737
10-Q2022-05-05fiscal Q1 202238800000950170-22-007806
10-K2022-03-01fiscal FY 2021491250000950170-22-002519
10-Q2021-11-04fiscal Q3 2021421170000950170-21-003053
10-Q2021-08-05fiscal Q2 2021421120000950170-21-000946
10-Q2021-05-06fiscal Q1 202144900001564590-21-024969
10-K2021-02-24fiscal FY 2020501220001564590-21-008081
10-Q2020-11-05fiscal Q3 2020421190001564590-20-051302
10-Q2020-08-06fiscal Q2 2020421150001564590-20-037722
10-Q2020-05-07fiscal Q1 202044920001564590-20-022844
10-K2020-02-27fiscal FY 2019501380001564590-20-007395
10-Q2019-11-07fiscal Q3 2019431170001564590-19-041726
10-Q2019-08-07fiscal Q2 2019421120001564590-19-030054
10-Q2019-05-09fiscal Q1 201942850001564590-19-017968
10-K2019-02-27fiscal FY 2018451350001564590-19-004890
10-Q2018-11-06fiscal Q3 201839980001564590-18-027387
10-Q2018-08-08fiscal Q2 201837950001564590-18-020448
10-Q2018-05-09fiscal Q1 201834710001564590-18-012382
10-K2018-03-07fiscal FY 2017411190001564590-18-004727
10-Q2017-11-07fiscal Q3 201735940001564590-17-022252
10-Q2017-08-07fiscal Q2 201734900001564590-17-016005
10-Q2017-05-05fiscal Q1 201735720001564590-17-008943
10-K2017-03-02fiscal FY 2016391250001564590-17-003229
10-Q2016-11-03fiscal Q3 201636980001564590-16-027405
10-Q2016-08-03fiscal Q2 201636980001564590-16-022364
10-Q2016-05-06fiscal Q1 201637740001564590-16-018134
10-K2016-03-07fiscal FY 2015401250001564590-16-014091
10-Q2015-11-23fiscal Q3 201537960001564590-15-010977

Inspect the source

Entity
CytomX Therapeutics, Inc. / CIK 0001501989
Captured
2026-09-20T09:11:45.284Z
SEC response SHA-256
5b42506ede2a678f55147a208e23021683fa4501c0a8daefcc1079a51395cbde

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001501989.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))